Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep;24(3):597-612.
doi: 10.1007/s10561-022-10060-2. Epub 2022 Dec 16.

The promising approach of MSCs therapy for COVID-19 treatment

Reza Samanipour  1 , Sara Tabatabaee  2 , Mahsa Delyanee  3 , Amirhossein Tavakoli  4
Affiliations
Review

The promising approach of MSCs therapy for COVID-19 treatment

Reza Samanipour et al. Cell Tissue Bank. 2023 Sep.

Abstract

Several ongoing investigations have been founded on the development of an optimized therapeutic strategy for the COVID-19 virus as an undeniable acute challenge for human life. Cell-based therapy and particularly, mesenchymal stem cells (MSCs) therapy has obtained desired outcomes in decreasing the mortality rate of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), mainly owing to its immunoregulatory impact that prevents the overactivation of the immune system. Also, these cells with their multipotent nature, are capable of repairing the damaged tissue of the lung which leads to reducing the probability of acute respiratory distress syndrome (ARDS). Although this cell-based method is not quite cost-effective for developing countries, regarding its promising results in order to treat SARS-COV-2, more economical evaluation as well as clinical trials should be performed for improving this therapeutic approach. Here in this article, the functional mechanism of MSCs therapy for the treatment of COVID-19 and the clinical trials based on this method will be reviewed. Moreover, its economic efficiency will be discussed.

Keywords: Acute respiratory distress dyndrome (ARDS); COVID-19; Cell therapy; Clinical trials; Mesenchymal stem cells (MSCs).

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The MSCs therapy functional mechanism for COVID-19 treatment
See this image and copyright information in PMC

References

    1. Abraham A, Krasnodembskaya A. Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome. Stem Cells Transl Med. 2020;9(1):28–38. doi: 10.1002/sctm.19-0205. - DOI - PMC - PubMed
    1. Abreu SC, Lopes-Pacheco M, Weiss DJ, Rocco PR. Mesenchymal stromal cell-derived extracellular vesicles in lung diseases: current status and perspectives. Front Cell Dev Biol. 2021;9:600711. doi: 10.3389/fcell.2021.600711. - DOI - PMC - PubMed
    1. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(4):1815–1822. doi: 10.1182/blood-2004-04-1559. - DOI - PubMed
    1. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Lee M. Characteristics and outcomes of 21 critically ill patients with COVID-19 Wash State. Jama. 2020;323(16):1612–1614. doi: 10.1001/jama.2020.4326. - DOI - PMC - PubMed
    1. Atashi F, Modarressi A, Pepper MS. The role of reactive oxygen species in mesenchymal stem cell adipogenic and osteogenic differentiation: a review. Stem Cells Dev. 2015;24(10):1150–1163. doi: 10.1089/scd.2014.0484. - DOI - PMC - PubMed